Tenax Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Tenax Therapeutics, Inc. on January 9, 2026, covering events occurring on January 6, 2026. The company is incorporated in Delaware and trades on The Nasdaq Stock Market LLC under the symbol TENX.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and executive compensation rather than financial performance.
Material Changes
On January 6, 2026, the Company entered into a second amendment to the Executive Employment Agreement with Dr. Stuart Rich, Chief Medical Officer. Key changes include:
- Dr. Rich will devote an average of four days per week to his duties, effective January 1, 2026.
- His annual base salary will be prorated to reflect the modified work schedule.
- The amendment was approved by the Board on December 22, 2025.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on future performance, or discussion of risks and contingencies. The document strictly reports the amendment to an executive employment contract.
Investor Verification Checklist
- Review Exhibit 10.1 for the full terms of the Second Amendment to the Executive Employment Agreement.
- Verify the specific prorated salary amount and any changes to equity or bonus structures not detailed in the summary.
- Confirm the impact of the reduced work schedule on the Company's medical operations and pipeline development.